SAN

81.75

+0.86%↑

MRK1

118.45

-0.13%↓

SHL.DE

44.38

+0.7%↑

ARGX

731.8

-1%↓

FRE

47.76

-0.27%↓

SAN

81.75

+0.86%↑

MRK1

118.45

-0.13%↓

SHL.DE

44.38

+0.7%↑

ARGX

731.8

-1%↓

FRE

47.76

-0.27%↓

SAN

81.75

+0.86%↑

MRK1

118.45

-0.13%↓

SHL.DE

44.38

+0.7%↑

ARGX

731.8

-1%↓

FRE

47.76

-0.27%↓

SAN

81.75

+0.86%↑

MRK1

118.45

-0.13%↓

SHL.DE

44.38

+0.7%↑

ARGX

731.8

-1%↓

FRE

47.76

-0.27%↓

SAN

81.75

+0.86%↑

MRK1

118.45

-0.13%↓

SHL.DE

44.38

+0.7%↑

ARGX

731.8

-1%↓

FRE

47.76

-0.27%↓

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

20.45

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.25

Max

20.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

17.65

76.798

Dividendų pajamingumas

1.7

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.70%

2.37%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

67M

1.5B

Ankstesnė atidarymo kaina

20.45

Ankstesnė uždarymo kaina

20.45

Naujienos nuotaikos

By Acuity

50%

50%

159 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-17 23:50; UTC

Karštos akcijos

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

2025-12-17 23:20; UTC

Uždarbis

Correction to Micron Logs Sales Jump Article

2025-12-17 23:07; UTC

Uždarbis

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

2025-12-17 21:37; UTC

Uždarbis

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

2025-12-17 23:53; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

2025-12-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

2025-12-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

2025-12-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

2025-12-17 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

2025-12-17 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

2025-12-17 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

2025-12-17 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

2025-12-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

2025-12-17 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

2025-12-17 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

2025-12-17 22:49; UTC

Rinkos pokalbiai

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

2025-12-17 21:58; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-17 21:46; UTC

Uždarbis

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

2025-12-17 21:20; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:10; UTC

Uždarbis

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:05; UTC

Uždarbis

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

2025-12-17 21:04; UTC

Uždarbis

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

2025-12-17 21:04; UTC

Uždarbis

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

2025-12-17 21:02; UTC

Uždarbis

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

2025-12-17 21:01; UTC

Uždarbis

Micron Technology 1Q Rev $13.64B >MU

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

159 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat